MNCs Can Access Asian Markets Faster With Bridging Studies – Parexel Exec
This article was originally published in The Pink Sheet Daily
With local variations, Asian countries are accepting Phase III data from multinational studies that include patients from their country – even if they live in Los Angeles.
You may also be interested in...
HONG KONG - Looking to shore up a weakness in its ability to transform research into commercially viable products and strengthen its position in the biotech and pharmaceutical sectors, the Taiwan government announced several measures in the past few weeks that will see it create a research and development center and a government-run venture capital fund
SEOUL - South Korea is drawing more Phase I and Phase II clinical trials from its former foothold in Phase III and post-approval trials, Korea National Enterprise for Clinical Trials reported
U.S.-based contract research organization Parexel International Corp. announced its buyout of Taiwan's Apex International Clinical Research Co. on Sept. 26. Parexel bought the firm, which will now operate as Parexel Apex International, for $50.9 million. Parexel hopes its partnership with Apex will help it to access Asia's growing healthcare and pharmaceutical markets. Apex already supplies the regional medical industry with a number of services including consultations, clinical monitoring, data management, and site management. Asides from its Taiwan headquarters, which has about 350 employees, Apex has several other locations around the region, including China, Hong Kong, Korea, India, Singapore, the Philippines, Malaysian, Indonesia, Thailand, Australia, and New Zealand. Apex's Taiwan location is especially advantageous in light of the fact that as of June 6, 2007, Taiwan had more clinical trials than anywhere else in the area with 532 active trials. Japan came in second with 328, China had 275, and Indian 270. (Click here for more - May Require Free Registration